• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

WHO Issues Two Reports Detailing Global Problem Of Substandard And Falsified Medicines

28/11/2017 by William New, Intellectual Property Watch Leave a Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

The World Health Organization today issued two substantive reports on the problem of substandard and falsified medicines around the world, finding among other things that an estimated one in 10 medical products in low and middle income countries is either substandard or falsified.

WHO headquarters

WHO launched its Global Surveillance and Monitoring System for substandard and falsified medicines, vaccines and in-vitro diagnostic tests in July 2013. This first report is based on data collected during the first 4 years of operation up to 30 June 2017.

The second report is a study on the public health and socioeconomic impact of substandard or falsified medical products conducted by WHO and the Member State Mechanism

The reports are available on the WHO website here.

“Since 2013, WHO has received 1500 reports of cases of substandard or falsified products,” the UN agency said in a release. “Of these, antimalarials and antibiotics are the most commonly reported. Most of the reports (42%) come from sub-Saharan Africa, 21% from the Americas and 21% from the European region.”

“This is likely just a small fraction of the total problem and many cases may be going unreported,” it said. “For example, only 8% of reports of substandard or falsified products to WHO came from the WHO Western Pacific region, 6% from the Eastern Mediterranean and just 2% from the South-East Asia region.”

“In conjunction with the first report from the Global Surveillance and Monitoring System published today, WHO is publishing research that estimates a 10.5% failure rate in all medical products used in low- and middle-income countries,” it said.

“[T]hese two reports represent the most comprehensive compilation to date of data related to substandard and falsified medical products and are a first step towards better understanding their public health and socioeconomic impact,” WHO said.

Intellectual Property Watch will update this story with in-depth details on the reports and the press briefing with WHO officials shortly.

 

Image Credits: Catherine Saez

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

William New may be reached at wnew@ip-watch.ch.

Creative Commons License"WHO Issues Two Reports Detailing Global Problem Of Substandard And Falsified Medicines" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP Policies, Language, Themes, Venues, Copyright Policy, Enforcement, English, Health Policy Watch, Human Rights, Patents/Designs/Trade Secrets, Trademarks/Geographical Indications/Domains, WHO

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Top Global Health stories

New WHO Director Tedros’s Opening Vision: People First

Enter The African Medicines Agency, Continent’s First Super-Regulator?

More health stories...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.